The finalization of the United States’ withdrawal from the World Health Organization (WHO) marks a seismic shift in global health governance, one that exposes critical uncertainties for healthcare leaders, public health systems, and the infrastructure supporting pandemic readiness. While federal leadership characterized the move as a necessary correction to institutional failure, the long-term implications for operational coordination, global surveillance, and regulatory alignment remain unresolved.

The healthcare policy landscape in the United States has again shifted with the unveiling of former President Donald Trump’s proposed Great Healthcare Plan. While the political context surrounding the proposal may spark predictable partisan reactions, the plan itself raises a deeper, more systemic challenge: how far can, and should, price transparency, consumer-directed benefits, and direct subsidies go in reshaping how healthcare is purchased, priced, and governed?

The recent $556 million settlement by Kaiser Permanente affiliates over inflated Medicare Advantage payments underscores a persistent and unaddressed compliance risk embedded within the risk adjustment ecosystem. The allegations point to systemic pressure on physicians to append diagnoses not considered during patient encounters, practices that, if validated, reveal how financial incentives tied to coding can distort clinical records and degrade payer trust.

The fourth federal extension of telemedicine prescribing flexibilities for controlled substances offers temporary relief, but not long-term certainty, for healthcare systems navigating hybrid care delivery. The joint decision by the Department of Health and Human Services and the Drug Enforcement Administration to prolong pandemic-era telemedicine allowances through the end of 2026 is framed as a move to protect patients.

The latest proposed updates to federal price transparency regulations signal a deeper acknowledgment of an uncomfortable truth: health care pricing data is now technically public, but still functionally unusable. The Centers for Medicare & Medicaid Services (CMS), working with the Departments of Labor and Treasury, aims to correct this mismatch by simplifying data formats, reducing redundancies, and making cost tools more accessible. But unless these changes are paired with a broader shift in how price transparency is operationalized across the system, their impact may remain symbolic rather than structural.

The U.S. Department of Health and Human Services (HHS) has issued a sweeping Request for Information (RFI) to identify how artificial intelligence (AI) can accelerate clinical transformation across the American healthcare system. Framed as a call to harness AI for lower costs and improved care, the initiative invites input on everything from evolving reimbursement frameworks to rethinking regulatory pathways. But beneath the enthusiasm lies a complex set of operational, legal, and ethical dynamics that will shape whether these ambitions translate into scalable realities.

A newly unsealed federal indictment against a Los Angeles-area physician alleges a $45 million Medicare fraud scheme involving falsified Botox claims, exposing once again the operational vulnerabilities that continue to undermine the integrity of federal health programs. The charges against Dr. Violetta Mailyan include wire fraud and obstruction of justice, centered on billing for procedures that were medically unnecessary or never performed. While the case is still pending, it signals ongoing systemic exposure to high-value, low-detection fraud.

The Centers for Medicare & Medicaid Services (CMS) has proposed a new mandatory payment model aimed at lowering prescription drug costs for Medicare beneficiaries, a move that underscores both the urgency and complexity of reforming drug pricing in the United States. Dubbed the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model, the initiative introduces international price benchmarking and modified rebate structures to rein in spending under Medicare Part D. But while the model reflects an aggressive policy posture, it also raises significant implementation and equity questions as it moves toward a 2027 launch.